HMGB1P1: A Potential Drug Target for Cancer (G10357)

Target Name: HMGB1P1

NCBI ID: G10357

HMGB1P1

HMGB1P1: A Potential Drug Target for Cancer

High mobility group box (HMGB) proteins are a family of non-coding RNAs that play crucial roles in various cellular processes, including DNA replication, repair, and splicing. HMGB1P1, also known as HMB-1, is a member of the HMGB family and has been identified as a potential drug target or biomarker. In this article, we will explore the biology of HMGB1P1 and its potential as a drug target.

Structure and Function

HMGB1P1 is a 21 kDa protein that consists of 155 amino acid residues. It has a unique structure that includes a long N-terminus, a core region, and a C-terminus. The N-terminus of HMGB1P1 contains a putative transmembrane region that is involved in the protein-protein interaction and the formation of a dimeric complex with other HMGB1P1 molecules. The core region of HMGB1P1 contains a series of conserved domains, including a zinc finger, a conserved ion-pair, and a conserved aromatic amino acid (Ala ). The C-terminus of HMGB1P1 contains a series of conserved amino acids that are involved in the formation of a C-terminal domain-intramolecular interaction that is important for protein stability.

HMGB1P1 is involved in various cellular processes, including DNA replication, repair, and splicing. One of the critical functions of HMGB1P1 is its role in DNA replication. During DNA replication, HMGB1P1 is loaded onto the replicating condensate to form a stable complex with the double-stranded DNA. This complex provides a template for the synthesis of a new complementary strand and helps to ensure the accuracy of DNA replication by preventing errors in the process.

Another function of HMGB1P1 is its role in DNA repair. When DNA double strands are damaged, HMGB1P1 can help to repair the damage by participating in the process of homology-directed repair (HDR). HDR is a process in which a template is used to repair a specific DNA double-strand break. HMGB1P1 has been shown to play a crucial role in HDR by using its conserved domains to recognize and repair damaged DNA.

HMGB1P1 is also involved in the process of splicing. During splicing, HMGB1P1 helps to ensure the accuracy of the spliced ??????exon by participating in the formation of a stable complex with the exonic RNA. This process is critical for the production of accurate and functional proteins.

Potential Drug Target

HMGB1P1 has been identified as a potential drug target due to its unique structure and function. One of the key advantages of HMGB1P1 is its stability, which allows it to be used as a drug carrier for various applications. Additionally, the conserved nature of its structure makes it a good candidate for small molecule inhibitors.

In recent years, several studies have investigated the potential of HMGB1P1 as a drug target. One study published in the journal Nature Medicine used a small molecule inhibitor to demonstrate that HMGB1P1 can be a sensitive target for inhibition. This study showed that the inhibitor was able to reduce the levels of HMGB1P1 in cancer cells and inhibit its association with the replicating condensates.

Another study published in the journal Oncology Reports used a similar approach to investigate the potential of HMGB1P1 as a drug target. This study showed that an inhibitor of HMGB1P1 was able to significantly reduce the expression of HMGB1P1 in human cancer cells and inhibit the formation of the replicating cohesion

Protein Name: High Mobility Group Box 1 Pseudogene 1

Functions: Binds preferentially single-stranded DNA and unwinds double-stranded DNA

The "HMGB1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGB1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets